Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Investors Are Less Pessimistic Than Expected

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) price-to-sales (or "P/S") ratio of 37x may look like a poor investment opportunity when you consider close to half the companies in the Biotec

Simply Wall StMay 14 03:17 ET

Zejing Pharmaceutical (688266.SH): net loss of 279 million yuan in 2023

Gelonghui, April 19丨Zejing Pharmaceutical (688266.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 386 million yuan, an increase of 27.83% over the previous year; net profit attributable to shareholders of listed companies - 279 million yuan; basic earnings per share - 1.09 yuan.

Gelonghui FinanceApr 19 05:56 ET

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Market Cap Dropped CN¥1.2b Last Week; Retail Investors Bore the Brunt

Key Insights Suzhou Zelgen BiopharmaceuticalsLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 13 investor

Simply Wall StApr 17 19:04 ET

Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials

Suzhou Zejing Biopharmaceutical (SHA:688266) said the National Medical Products Administration (NMPA) issued a Clinical Trial Approval for its Jacktinib Cream to treat non-segmental vitiligo, accordin

MT NewswiresApr 12 03:15 ET

Zejing Pharmaceutical (688266.SH): Jacketinib hydrochloride cream obtained drug clinical trial approval

Zejing Pharmaceutical (688266.SH) issued an announcement. The company recently received from the State Drug Administration (hereinafter referred to as...

Zhitong FinanceApr 11 03:39 ET

Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe

Simply Wall StMar 4 17:54 ET